Table 5.
Factors associated with overall survival of patients with BCBM
| Variable | Hazard Ratio a | 95% CI a | p value a |
|---|---|---|---|
| Univariate analysis | |||
| Age at BrM diagnosis, yr | |||
| ≤60 | 1 | ||
| >60 | 1.87 | 1.27–2.73 | .001 |
| Site of metastasis at BCBM diagnosis | |||
| Lung | |||
| No | 1 | ||
| Yes | 1.70 | 1.10–2.50 | .029 |
| Liver | |||
| No | 1 | ||
| Yes | 1.90 | 1.30–2.80 | .002 |
| Bone | |||
| No | 1 | ||
| Yes | 1.20 | 0.77–1.80 | .68 |
| Node | |||
| No | 1 | ||
| Yes | 1.30 | 0.90–2.00 | 0.21 |
| Neurological symptom at time of BrM diagnosis | |||
| No | 1 | ||
| Yes | 1.70 | 1.00–3.00 | .047 |
| Subtype | .002 | ||
| HR+/HER2− | 1 | ||
| HER2+ | 0.55 | 0.35–0.86 | .009 |
| Triple negative | 1.19 | 0.75–1.88 | .460 |
| First local treatment modality | <.0001 | ||
| WBRT | 1 | ||
| Surgery | 0.20 | 0.08–0.49 | <.001 |
| SRS | 0.37 | 0.22–0.63 | <.001 |
| No treatment | 0.95 | 0.38–2.34 | .907 |
| Multivariate analysis | |||
| Age at BrM diagnosis, yr | |||
| ≤60 | 1 | ||
| >60 | 1.94 | 1.32–2.86 | <.001 |
| Neurological symptom at time of BrM diagnosis | |||
| No | 1 | ||
| Yes | 1.84 | 1.06–3.18 | .030 |
| First local treatment modality | |||
| WBRT | 1 | ||
| Surgery | 0.19 | 0.08–0.48 | <.001 |
| SRS | 0.39 | 0.23–0.65 | <.001 |
| No treatment | 1.04 | 0.42–2.59 | .927 |
| Subtype | |||
| HR+/HER2− | 1 | ||
| HER2+ | 0.66 | 0.42–1.04 | .073 |
| Triple negative | 1.39 | 0.88–2.22 | .160 |
a
Patients with unknown breast cancer subtype were excluded from this analysis; 587 patients with HR+/HER2‐, HER2+ or triple negative breast cancer were included.
Abbreviations: BCBM, breast cancer brain metastasis; BrM, brain metastasis; HR, hormone receptor; MBC, metastatic breast cancer; SRS, stereotactic radiosurgery; TNBC, triple‐negative breast cancer; WBRT, whole brain radiation therapy.